Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thx for update
Who cares. This one could fly to high on decent buying volume
This looks so thin on upside it could be 10 cents so quick
And it lost more they previously. Zero communication
Like I said earlier all good news coming in. It should rock soon.
All good news coming in and investors conference coming this stock is primed for nice run.
Holding strong before conference. I’m imagining it’ll attract more investors when conference happens
And he’s back again with 5000 on ask at 14
And always 5 or 6k on ask. Same this morning
They are trying to bring price down with 5000 shares on ask. Ridiculous.
Looks very strong and ready for breakout.
This may go quick over.20
Back at .14 weird game
What news?
There’s couple of them playing with it
What’s going on here
Can you elaborate what this means? Thank you!
No comment
I’m back in. This will go over buck again.
Looks like 103 at open
I just got some
Not sure but I’m sure it’ll catch up and pass when revenues come.
Even people who we’re never both on amazon will have to do it now
It’ll be huge.
I agree. I myself purchased ton of stuff in last week or so on amazon. My target is $2500 by the end of the year.
Wow. $20
ADM Tronics Provides Update on Operations During COVID-19 Coronavirus Outbreak
Source: InvestorsHub NewsWire
Northvale, NJ -- March 17, 2020 -- InvestorsHub NewsWire -- ADM Tronics Unlimited, Inc. (OTCQB – ADMT) confirms that operations at its research, development, engineering and FDA-registered Medical Device manufacturing facility are currently continuing during the COVID-19 outbreak.
The COVID-19 situation continues to evolve rapidly, locally as well as nationwide and globally. ADMT develops and manufactures diversified products, including medical devices and packaging formulations for foods and pharmaceuticals. ADMT believes many of these technologies will remain in demand during this period and anticipates continued production and operations. ADMT has communicated with its customers and suppliers to confirm operations are continuing.
“We are grateful to our family of employees for their dedication during this difficult time,” stated Andre’ DiMino, ADMT President. “The health of our employees, their families and our community is paramount, so we are exercising caution to help avoid spread of the disease, while at the same time maintaining operations. Products we develop and manufacture are needed for the medical and other industries we serve. We want to maintain our ability to produce these for our loyal customers, and the patients and users needing them."
Here is information about some ADMT customers:
1. Yesterday, Endonovo Therapeutics, Inc., an ADMT customer, announced it is providing SofPulse units for investigational use to evaluate inhibition of inflammatory symptoms associated with COVID-19. SofPulse units are non-invasive, therapeutic medical devices that were developed and are manufactured by ADMT for Endonovo.
2. ADMT received the following statement from Jerry Katzman, MD, “As CEO of SteriView, RetinalGeniX, and Intubation Sciences, to name a few, I am grateful for the success and production schedule that ADM Tronics has been following, and has continued to follow, in developing, R&D testing, and producing our products during these challenging times. Simply put, ADMT has stayed on target in delivering our suite of products and design schedule as needed to meet our requirements to date, and in the months to come.”
3. ADMT has been developing and manufactured for Origin, Inc. the IonoJet™, which allows for targeted delivery of Nitric Oxide ("NO"), produced at the point of therapy from room air, in a thermal plasma. Michael Preston, Chairman and President of Origin, Inc., stated, "Like other nitric oxide companies, we have recognized the potential ability of NO to stop the replication of the corona viruses. We believe there may be fundamental problems with the other approaches we have seen and are working to address these in a novel system that will allow NO to be administered effectively. ADMT has been key to our development and will play an important part in our future.”
4. ADMT is Assisi Animal Health’s development and manufacturing partner for its targeted Pulsed Magnetic Field (tPEMF™) therapeutic devices for the animal healthcare market. L. John Wilkerson, PhD, Assisi’s Chairman, has reached out to distributors, veterinary clinics, and pet owners assuring them that “As we all do our parts in fighting COVID-19, thanks to our long and strong relationship with Andre’ DiMino and the ADM Tronics team, Assisi will be able to continue to supply our customers with the products they rely on to relieve pain and inflammation and to treat anxiety disorders in companion animals.”
Wish that I had some cash available. Great buy.
I feel this might be a year for breakout with all new contracts. Revenues has improved and almost back to profitability. They are generating cash.
Pretty good 10Q
There’s nothing firmed here and ceo posting on this board????
Like I said in my post ‘‘tis will most likely come down.
Experienced, Successful Leadership:
The scientific team at RetinalGeniX is led by Lloyd Paul Aiello, M.D., Ph.D., Head of Joslin Diabetes Centers’ Section on Eye Research, Director of Joslin’s Beetham Eye Institute, and Associate Professor of Ophthalmology at Harvard Medical School.
Dr. Aiello is the author of more than 60 original papers and over 100 publications and the recipient of 20 national and international awards. He has served as Chair for two Medical Science Review Committees of the Juvenile Diabetes Research Foundation, the American Diabetes Association Lions SightFirst Diabetic Retinopathy Research Program and the National Institutes of Health sponsored Diabetic Retinopathy Clinical Research Network.
ADM Tronics to Develop Patented, Next-Generation Ophthalmic Diagnostic System for RetinalGeniX Technologies, Inc.
Northvale, NJ -- January 13, 2020 -- InvestorsHub NewsWire -- ADM Tronics Unlimited, Inc. (OTCQB: ADMT) announced that RetinalGeniX Technologies, Inc. (“RTI”), has entered into an engineering development agreement for ADMT to develop and manufacture RTI’s patented, next-generation ophthalmic diagnostic technology known as the RetinalGeniX™ system.
The RetinalGeniX system is a cost-effective, ultra-wide imaging system to examine the periphery of the retina for the detection of early signs of diabetic retinopathy (“DR”) without dilating a patient’s pupils. RetinalGeniX was developed by researchers at RTI and is covered by three patents.
ADMT will develop and engineer the RetinalGeniX system to meet regulatory requirements and for quantity manufacturing in ADMT’s FDA-Registered Medical Device Manufacturing Facility in Northvale, NJ. Once the commercial-ready design of the RetinalGeniX system is completed, ADMT will support RTI in regulatory submission requirements for US FDA and international distribution to the ophthalmic and ophthalmology markets.
Jerry Katzman, MD, Chairman, President and CEO of RTI, stated, “We are pleased to be working with ADM Tronics to bring the RetinalGeniX system to market readiness. There is a significant need for a simpler and more affordable device for uncomplicated but accurate imaging of a person’s retina to detect symptoms of diabetic retinopathy. I know our RetinalGeniX system fills that need and I am confident ADMT can help us to bring this great technology to fruition.”
DR is a leading cause of vision loss globally. Of an estimated 285 million people with diabetes mellitus, about one-third, over 100 million, have signs of DR with approximately one-third of those, or 35 million, threatened with blindness due to diabetic maculopathy. Early detection of diabetes, by observing vascular changes in the peripheral retina, not only serves as an early warning for diabetes but also signals vascular cerebral pathology and early signs of dementia. Early diagnosis leads to more favorable outcomes in both diseases. This technology will facilitate the mass screening of large populations.
“We are excited that RTI has chosen our company for this important project that can help so many people around the world,” stated Andre’ DiMino, President and CEO of ADMT. “Our engineering and regulatory teams look forward to working with Dr. Katzman and researchers at RTI to bring the RetinalGeniX system to commercialization.”
RTI is an emerging medical device company focused on commercializing the next generation of cost-effective, ultra-wide imaging technologies to examine the periphery of the retina, at up to a 200° field of view, to detect early signs of diabetic retinopathy. “We are dedicated to developing technologies that advance the next generation of diagnostics. Detected early and treated effectively, retinopathy can be stopped so that vision can be maintained. The proliferation of tools making early diagnosis easy and inexpensive is a critical factor in broadening care,” stated Dr. Katzman. “Our relationship with ADM Tronics for engineering the RetinalGeniX system helps us to advance our efforts.”
You are smart. This will most likely come even more lover since there’s no firm contracts news.
Nice. I’m expecting very good year for this company.
This stock doesn’t give any ground. It’ll be fun to watch when it breaks
They want to save money. Big company like tile shop TSH did it recently.